---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-017114"
form_type: "8-K/A"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-06-14T23:59:59+00:00"
generated_at: "2026-06-25T01:53:06.467706+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology shareholders reject advisory vote on executive compensation at 2022 annual meeting

## Summary
- Corrected voting results show say-on-pay failed: 7.93M For, 7.36M Against, 2.02M Abstain, 12.06M broker non-vote.
- All seven director nominees elected; BDO USA ratified as auditor; amendment to 2021 Omnibus Equity Plan approved.
- Amendment filed to correct original 8-K error in Proposal 4 (advisory vote on executive compensation) results.

## SEC filing metadata
- accession: 0001628280-22-017114
- form_type: 8-K/A
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/0001628280-22-017114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/crdf-20220609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-017114
- JSON: https://secwatch.observer/filing/0001628280-22-017114.json
- Plain text: https://secwatch.observer/filing/0001628280-22-017114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.